Table 5.
Selected ongoing phase III trials investigating targeted therapies in combination with ET.
| Target | Agent | ET agent | ClinicalTrials.gov identifier | Estimated enrollment (n) |
|---|---|---|---|---|
| CDK4/6 | Palbociclib | Letrozole | NCT01740427 | 450 |
| PALOMA2 | ||||
| CDK4/6 | Ribociclib | Letrozole | NCT01958021 | 650 |
| MONALEESA 2 | ||||
| CDK4/6 | Abemaciclib | Letrozole or anastrozole | NCT02246621 | 450 |
| MONARCH 3 | ||||
| PI3K | BKM120 | Fulvestrant | NCT01633060 | 615 |
| PI3K | Taselisib | Fulvestrant | NCT02340221 | 600 |
| Sandpiper | ||||
| mTOR | Everolimus | Fulvestrant and anastrozole | NCT02137837 | 825 |
| S1222 | ||||
| HER2 | Lapatinib and trastuzumab | Aromatase inhibitor | NCT01160211 | 525 |
| HDAC | Entinostat | Exemestane | NCT02115282 | 600 |
CDK, cyclin-dependent kinase; ET, endocrine therapy; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor type 2; mTOR, mammalian target of rapamycin.